Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that ...

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...

On Monday, AstraZeneca Plc AZN shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for ...

AstraZeneca (AZN) shares have been enjoying a strong bull run ever since falling to a low of $55 in mid-October last year - their lowest value since April 2021. Across a five-year period, overall ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

AstraZeneca stock edged lower despite the US FDA granting accelerated approval for the company’s new breast cancer pill ...

Pharma company AstraZeneca has publicly released preclinical data from more than 50 of its medicines in order to find new drug combinations for cancer treatments. The data AstraZeneca released will be ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic ...

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; ...

AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be ...

AstraZeneca (NASDAQ:AZN) reported mixed results from a Phase 3 clinical trial for its lung cancer drug datopotamab deruxtecan, or Dato-Dxd, in the treatment of advanced lung cancer. The British ...

Achilles Therapeutics plc has announced the transfer of data and samples from its TRACERx Non-Small Cell Lung Cancer study and its Material Acquisition Platform (MAP) to AstraZeneca for a total ...